Pascal Maisonobe, MS

Biometry
Ipsen, France

Poster(s):

• 400 Section - A randomized, double-blind, head-to-head, crossover study comparing the clinical safety and efficacy of abobotulinumtoxinA with onabotulinumtoxinA when treating adults with upper limb spasticity
  Wednesday, May 20, 2026

  6:00 PM - 7:30 PM PT

• 1000 Section - Differences in the time to abobotulinumtoxinA reinjection for children with cerebral palsy with and without the presence of mixed dystonia: Post-hoc analysis of a randomized clinical trial
  Wednesday, May 20, 2026

  6:00 PM - 7:30 PM PT

• 1000 Section - Impact of regional differences in use of injection guidance on goal attainment following repeat abobotulinumtoxinA injections: Subgroup analysis of the AboLiSh observational study
  Wednesday, May 20, 2026

  6:00 PM - 7:30 PM PT

• 300 Section - Sensitivity and specificity of the Post-stroke Spasticity Monitoring Questionnaire (PSMQ) for remote monitoring of spasticity development: Interim analysis from an ongoing epidemiological study
  Tuesday, May 19, 2026

  6:00 PM - 7:30 PM PT